Prospective assessment of donor blood screening for antibody to hepatitis C virus and high-titer antibody to HBcAg as a means of preventing posttransfusion hepatitis

Hepatology ◽  
1993 ◽  
Vol 18 (2) ◽  
pp. 235-239 ◽  
Author(s):  
Susumu Takano ◽  
Masao Omata ◽  
Masao Oht ◽  
Yoichi Satomura
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
High Titer ◽  
Donor Blood ◽  
Posttransfusion Hepatitis ◽  
Prospective Assessment ◽  
Blood Screening

scholarly journals BRIEF OVERVIEW ON HEPATITIS C VIRUS IMMUNOASSAYS

2016 ◽  
Vol 4 (1) ◽  
pp. 178-184
Author(s):  
Rajesh Sharma ◽  
Pankaj Sharma ◽  
Gaush Talat ◽  
Praveen Gautam ◽  
Reba Chhabra ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Immunosorbent Assay ◽  
Enzyme Linked Immunosorbent Assay ◽  
Donor Blood ◽  
Chemiluminescence Immunoassay ◽  
Window Period ◽  
Sensitivity Specificity ◽  
Blood Screening

The publication deals with a brief overview of Hepatitis C Virus (HCV) and donor blood screening for HCV by using conventional Rapid, Enzyme Linked Immunosorbent Assay (ELISA) and Chemiluminescence Immunoassay (CLIA) also. The advantages of various generation of HCV tests in terms of sensitivity, specificity and reduction in window period are discussed.

scholarly journals Reduction of incidence fo post-transfusion hepatitis(PTH) by donor blood screening for hepatitis C virus(HCV) antibody.

1991 ◽  
Vol 37 (5) ◽  
pp. 632-637
Author(s):  
Ryushi Shimoyama ◽  
Shinichi Sakaya ◽  
Toshiaki Kato ◽  
Toshie Nakase ◽  
Hisami Ikeda ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Donor Blood ◽  
Post Transfusion Hepatitis ◽  
Hcv Antibody ◽  
Blood Screening

scholarly journals History of posttransfusion hepatitis

1997 ◽  
Vol 43 (8) ◽  
pp. 1487-1493 ◽  
Author(s):  
Leslie H Tobler ◽  
Michael P Busch
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Hepatitis B ◽  
Hepatitis Virus ◽  
Hepatitis B Surface Antigen ◽  
Substantial Reduction ◽  
Surrogate Marker ◽  
Core Antigen ◽  
Viral Agent ◽  
Posttransfusion Hepatitis

Abstract The risk of hepatitis virus transmission from transfusions has declined dramatically from that of the 1940s when posttransfusion hepatitis (PTH) was first appreciated. Introduction of hepatitis B surface antigen screening and conversion to volunteer donors for whole-blood donations in the late 1960s and early 1970s led to substantial reduction in PTH cases. However, up to 10% of the recipients continued to develop PTH, most cases of which were attributed to an unknown non-A, non-B viral agent. Implementation of surrogate marker testing (i.e., alanine aminotransferase and anti-hepatitis B virus core antigen) for residual non-A, non-B hepatitis in the late 1980s reduced the per unit risk of PTH from 1 in 200 to about 1 in 400. Hepatitis C virus was discovered in 1989 and quickly was established as the causative agent of >90% of non-A, non-B PTH. Introduction of progressively improved antibody assays in the early 1990s reduced the risk of PTH due to hepatitis C virus to about 1 in 100 000. Although additional hepatitis viruses exist (e.g., hepatitis G virus), these appear to be minor contributors to clinical PTH, which has been virtually eradicated.

Evaluation of Antibodies to Hepatitis C Virus in a Long-Term Prospective Study of Posttransfusion Hepatitis Among Thalassemic Children

1993 ◽  
Vol 16 (4) ◽  
pp. 458-464 ◽  
Author(s):  
Maria Eliana Lai ◽  
Stefano De Virgilis ◽  
Francesca Argiolu ◽  
Patrizia Farci ◽  
Anna P. Mazzoleni ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Prospective Study ◽  
Posttransfusion Hepatitis
Sign in / Sign up

Export Citation Format

Share Document